

Patient Name Doe, John			Genzyme Order # 12-3456789	Genzyme Specimen # 50268812-SF,	Genzyme Case # 12345678
Birth Date 10/21/1932	Age 77 Y	Gender Male	Client Specimen # CS-QA	Genzyme Account # 123456	
Referring Physician Ordering Doctor, MD		Treating Physician Tel: 513-555-1234	Client Lab ID CL-QA	City Hospital 1 City Avenue	
Tel: 513-555-1234		Tel: 513-555-1212	Client Hospital ID CH-QA	Suite 1 Anywhere	ST 12345
Fax: 513-555-1235		Fax: 513-555-1213	Container(s) Received 1 Block Paraffin, 1 Fixative Formalin, 2 Green Top Tube 5ml, 1 Slide Paraffin, 1 Slide Stained	USA	
Collection Date 02/07/2010 11:11 AM	Received Date 02/07/2010 9:35 PM	Processed Date 02/08/2010 8:45 AM			

Clinical Summary and Indication History of CLL transforming to Richter (status post BM transplant); now severe pancytopenia. Evaluate for lymphoma.	Body Site Iliac Crest Iliac Crest	- Bone Marrow Aspirate - Bone Marrow Core
--	---	--

Interpretation

12% blasts and prominent phenotypic atypia of granulocytes/maturing myeloid cells suggestive of dyspoiesis/leftward shift. Diagnostic considerations include myelodysplastic syndrome (RAEB-2) and emerging acute myeloid leukemia (e.g. acute myelomonocytic leukemia).

No evidence of lymphoma. Due to the reticulin fibrosis often associated with lymphoid aggregates in the bone marrow, clonal lymphoid cells may not be identified by flow cytometry.

Phenotype

Blasts positive for CD13, CD33, CD34, CD4, CD38 and CD45; ~12-15%. Granulocytes/maturing myeloid cells display aberrant expression of CD10, CD11b, and CD16. Side scatter is decreased. The B-cells (3% of total) appear polytypic. The T-cells (3% of total) show no pan T-cell antigenic deletion (CD4:8=0.8:1). Monocytes = 16%.

Morphology

See Bone Marrow Morphology report.

Reviewing Pathologist

Wojciech Gorczyca, M.D., Ph.D.


800-447-5816

Viability & Abnormal Cells

Viability	80 %
Abnormal Cells	Yes
% Abnormal Cells	12-15 %
Cell Size	Large

Cell Distribution




Lymphocyte Gate	9.86 %
Blast Gate	20 %
Monocyte Gate	19.21 %
Granulocyte/Myeloid Gate	35.91 %
Erythroid/Plasma Cell Gate	1.96 %



Patient Name **Doe, John** Genzyme Order # **12-3456789** Genzyme Specimen # **50268812-SF,** Genzyme Case # **12345678**

The above estimated percentages are based on the scattergram of CD45 vs. Side Scatter. Not all cells in the "blast gate" may be true blasts, hence the blast gate percentage may not accurately reflect true blast count.

Lymphoid Associated		Myeloid Associated		Miscellaneous Markers	
sKappa	Negative	CD11b	Negative	CD10	Negative
sLambda	Negative	CD11c	Negative	CD34	Moderate
CD2	Negative	CD13	Moderate	CD117	Negative
CD3	Negative	CD14	Negative	CD38	Moderate
CD4	Dim	CD16	Negative	HLA-DR	Negative
CD5	Negative	CD33	Moderate-Bright	CD45	Moderate
CD7	Negative	CD64	Negative		
CD8	Negative				
CD19	Negative				
CD20	Negative				
CD56	Negative				



Additional Studies: Cytogenetics / FISH.

Electronically Signed By

Wojciech Gorczyca, M.D., Ph.D.

800-447-5816

Date

02/08/2010

This test was developed and its performance characteristics have been determined by Genzyme. It has not been cleared or approved by the FDA. The FDA has determined that such clearance or approval is not necessary. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing.